2 vials Save $47.50

Tirzepatide 10mg

Lyophilized research peptide

$112.49

Wolverine 10mg

2-component research blend

$124.99

Research bundle · 2 vials

Tirzepatide 10mg + Wolverine 10mg Research Bundle

USA Made, ≥99% Purity Per Compound

Separate retail vials: Tirzepatide 10mg; Wolverine 10mg (BPC-157 5mg + TB-500 5mg)
USA manufactured in a Certified GMP California and Arizona laboratory.
≥99% purity target per compound with third-party HPLC, mass spectrometry, and batch-specific COAs

Combined retail value$237.48

Bundle saving−$47.50

$189.98 $237.48 Save $47.50

Each vial ships in its original retail format with its own batch COA

Dispatched from a US warehouse within 48 hours, tracked

Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light

Disclaimer

For research purposes only. Not intended for human consumption, medical use, diagnosis, treatment, or prevention of disease.

Per-compound specifications

2 vials

Nothing in this bundle is co-formulated. Each vial keeps its own identity, purity target, and certificate, and is specified separately below.

Vial 01

Tirzepatide 10mg

Sequence

Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-γGlu-C20 diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

CAS: 2023788-19-2
Molecular mass: 4,813.53 g/mol
Purity target: ≥99%
Form: Lyophilized Powder

Vial 02

Wolverine 10mg

Sequences

BPC-157: GEPPPGKPADDAGLV; TB-500: Ac-LKKTETQ

CAS: BPC-157: 137525-51-0; TB-500: 885340-08-9
Molecular mass: BPC-157: 1,419.5 g/mol; TB-500: 889.01 g/mol
Purity target: ≥99%
Form: Lyophilized Powder

Form: 2 Separate Lyophilized Powders
Purity target: ≥99% per compound (3rd-Party HPLC Tested)
Origin: All Included Products: Synthesized, Formulated & Packaged in CA/AZ, USA
Storage: Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light

What is the Tirzepatide and Wolverine Research Bundle?

This two-vial bundle pairs Tirzepatide 10mg with Wolverine 10mg. Tirzepatide is a 39-amino-acid dual GIP/GLP-1 receptor agonist, while Wolverine combines BPC-157 5mg and TB-500 5mg in one formulated research vial.

The bundle supports controlled work across incretin-receptor, vascular, migration, and cytoskeletal pathways while keeping the retail products separate. It does not claim a combined clinical effect or create a new formulation.

How It Works

Tirzepatide activates GIPR and GLP-1R: The dual-receptor profile supports study of coordinated nutrient-responsive signaling.

Wolverine contains two defined peptide pathways: BPC-157 is studied in vascular and migration models, while TB-500 represents an actin-binding motif.

Separate retail vials preserve identity: Tirzepatide remains independent from the internally blended Wolverine formulation.

Analytical data

One certificate per vial

Independent third-party HPLC assesses each compound against its ≥99% purity target, while mass spectrometry confirms identity. For each vial, the results are documented in one combined, batch-specific COA report.

Lot: TI-89416
Reported: 2026-05-06
Identity (LC-MS): Confirmed
Purity (HPLC-UV): 99.46%
Net content: 10.01 mg
Appearance: White lyophilized powder

Download COA

Why Source from 321 Peptides?

Domestic accountability.

All included compounds are synthesized, manufactured, and finished in Certified GMP California and Arizona laboratory facilities—never sourced from overseas or Mexico. That means direct domestic supply-chain accountability from production through fulfillment.

Verification you can inspect.

Protected in transit.

Every included product is freeze-dried to help preserve stability during storage and shipping. Rapid domestic fulfillment reduces unnecessary time and handling.

Lot history 7 released lots

Every batch released under each vial in this bundle, with the figure reported for each. Vials are shipped from current stock.

Compound	Lot	Reported	Purity	Net content	COA
Tirzepatide 10mg	TI-89416	2026-05-06	99.46%	10.01 mg	Pending
	TI-89993	2026-05-02	99.58%	10.02 mg	Pending
	T5223	2026-04-23	99.84%	12.13 mg	PDF
	TI-88839	2026-04-08	99.49%	10.00 mg	Pending
Wolverine 10mg	WO-55604	2026-05-12	99.52%	10.08 mg	Pending
	WO-54450	2026-05-06	99.88%	10.06 mg	Pending
	WO-55027	2026-05-02	99.71%	10.07 mg	Pending

Frequently Asked Questions

What comes in the Tirzepatide and Wolverine bundle?

The bundle includes Tirzepatide 10mg; Wolverine 10mg (BPC-157 5mg + TB-500 5mg). Each retail product arrives in its original lyophilized vial with batch-specific COA documentation.

What is the difference between Tirzepatide and Wolverine?

Tirzepatide is a single dual-receptor peptide studied through GIPR and GLP-1R. Wolverine is a BPC-157 and TB-500 blend studied in vascular, cell-migration, and cytoskeletal models.

Is this bundle Mounjaro or Zepbound?

No, the Tirzepatide research vial is not Mounjaro, Zepbound, or another approved finished drug. Neither bundle vial is intended for human use or as a prescription substitute.